72411-52-0

Usage

Uses

Used in Pharmaceutical Research:
5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE is used as a research compound for the development of new drugs targeting various biological processes. Its unique structure and properties make it a promising candidate for drug discovery and design.
Used in Chemical Synthesis:
5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE is used as a building block in the synthesis of other organic compounds. Its versatile structure allows for the creation of a wide range of chemical entities with potential applications in various industries.
Used in Drug Development:
In the pharmaceutical industry, 5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE is used as a key intermediate in the synthesis of new drug candidates. Its unique chemical properties enable the development of innovative therapeutic agents with improved efficacy and selectivity.
Used in Medicinal Chemistry:
5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE is used as a starting material in medicinal chemistry for the design and optimization of novel drug molecules. Its pyrazole core and 4-fluorophenyl group provide a foundation for the exploration of new chemical space and the identification of potential drug candidates.
Used in Biochemical Research:
In the field of biochemical research, 5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE is used as a tool compound to study the interactions between small molecules and biological targets. Its unique structure allows researchers to probe the binding and activity of 5-(4-FLUOROPHENYL)-2H-PYRAZOL-3-YLAMINE against various proteins and enzymes, providing valuable insights into its potential therapeutic applications.

InChI:InChI=1/C9H8FN3/c10-7-3-1-6(2-4-7)8-5-9(11)13-12-8/h1-5H,(H3,11,12,13)

Upstream product

• 403-33-8 methyl 4-flurobenzoate 
• 456-22-4 4-Fluorobenzoic acid 
• 459-57-4 4-fluorobenzaldehyde 
• 4640-67-9 3-(4-fluorophenyl)-3-oxopropionitrile 
• 575433-43-1 3-(4-fluorophenyl)-2-propynenitrile 

Downstream Products

• 74073-51-1 3,4-bis-(4-fluoro-phenyl)-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7-one 
• 74073-50-0 3-(4-fluoro-phenyl)-4-pentafluorophenyl-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7-one 
• 1269515-32-3 2-(4-fluorophenyl)-6-nitropyrazolo[1,5-a]pyrimidine 
• 1269515-31-2 2,6-difluoro-N-(2-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(propylsulfonamido)benzamide 
• 1269515-33-4 2-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-6-amine 
• 333325-26-1 N-(3-(4-fluorophenyl)-1H-pyrazol-5-yl)-3-methylbenzamide 
• 1469779-15-4 C₂₇H₂₀F₂N₆O 
• 1469778-95-7 C₂₆H₁₈F₂N₆O 
• 1616388-37-4 3-(4-fluorophenyl)-5-nitro-1H-pyrazolo[3,4-b]pyridine 
• 1616385-55-7 N-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-6-yl]-4,5-dimethyl-1H-pyrazole-3-carboxamide 
• 1186610-19-4 3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-amine 
• 1616385-56-8 N-(3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-3,4-dimethyl-1H-pyrazole-5-carboxamide 
• 1264193-17-0 6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidine 
• 1374979-24-4 C₁₄H₁₅BrFN₃O 

Relevant academic research and scientific papers

Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-α]pyrimidin-7-amine

During our studies into preparing analogues of pyrazolopyrimidine as ATP synthesis inhibitors of Mycobacterium tuberculosis, a regiospecific condensation reaction between ethyl 4,4,4-trifluoroacetoacetate and 3-(4-fluorophenyl)-1H-pyrazol-5-amine was observed which was dependent on the specific reaction conditions employed. This work identifies optimized reaction conditions to access either the pyrazolo[3,4-β]pyridine or the pyrazolo[1,5-α]pyrimidine scaffold. This has led to the structural confirmation of the previously reported pyrazolopyrimidine 17b which was reported as pyrazolo[1,5-α]pyrimidine structure 2 which was corrected to pyrazolo[3,4-β]-pyrimidine 19.

Synthesis of Pyrazole Compounds by Using Sonication Method

A simple method for the synthesis of pyrazoles derivatives carried out by cyclization of cyanide with hydrazine hydrate by using sonication method. All the prepared compounds were characterized by 1H, 13C NMR and IR Spectroscopy.

Modular synthesis and antiproliferative activity of new dihydro-1H-pyrazolo[1,3-b]pyridine embelin derivatives

A set of new dihydro-1H-pyrazolo[1,3-b]pyridine and pyrazolo[1,3-b]pyridine embelin derivatives was synthesized through a multicomponent reaction from natural embelin, 3-substituted-5-aminopyrazoles and aldehydes. The synthesized compounds were evaluated against three hematologic tumor cell lines, HEL (acute erythroid leukemia), K-562 (chronic myeloid leukemia) and HL-60 (acute myeloid leukemia), and five breast cancer cell lines (SKBR3, MCF-7, MDA-MB-231, BT-549, HS-578T). The primate non-malignant kidney Vero cell line was used as the control of cytotoxicity. From the obtained results, some structure–activity relationships were out-lined. Furthermore, in silico prediction of physicochemical properties and ADME parameters were determined for the derivatives with the best antiproliferative values.

Synthesis of pyrazolopyrimidinones using a “one-pot” approach under microwave irradiation

A simple one-pot method for the microwave-assisted synthesis of substituted pyrazolo[1,5-a]pyrimidinones, a core scaffold in many bioactive and pharmaceutically relevant compounds, has been established. A variety of substituents was tolerated at the 2 and 5 positions, including functionalized aryls, heterocycles, and alkyl groups.

SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF

The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway

The success of bedaquiline as an anti-tubercular agent for the treatment of multidrug-resistant tuberculosis has validated the ATP synthesis pathway and in particular ATP synthase as an attractive target. However, limitations associated with its use in the clinic and the drug-drug interactions with rifampicin have prompted research efforts towards identifying alternative ATP synthesis inhibitors with differentiated mechanisms of action. A biochemical assay was employed to screen AstraZeneca's corporate compound collection to identify the inhibitors of mycobacterial ATP synthesis. The high-throughput screening resulted in the identification of 2,4-diaminoquinazolines as inhibitors of the ATP synthesis pathway. A structure-activity relationship for the quinazolines was established and the knowledge was utilized to morph the quinazoline core into quinoline and pyrazolopyrimidine to expand the scope of chemical diversity. The morphed scaffolds exhibited a 10-fold improvement in enzyme potency and over 100-fold improvement in selectivity against inhibition of mammalian mitochondrial ATP synthesis. These novel compounds were bactericidal and demonstrated growth retardation of Mycobacterium tuberculosis in the acute mouse model of tuberculosis infection.

Pyrazolopyrimidines and pyrazolotriazines with potent activity against herpesviruses

Synthesis of several pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines with potent activity against herpes simplex viruses is described. Synthetic approaches allowing for variation of the substitution pattern are o

Facile synthesis of fluorinated 2-aryl-5,7 bisalkyl pyrazolo pyrimidines from arylalkyne nitriles

Synthesis of pyrazolopyrimidines from fluorine substituted arylalkynenitriles is described. Arylalkynenitriles 1a-d reacted with hydrazine to give 5-aryl-3-amino-2H-pyrazoles 2a-d. The condensation of aminopyrazoles with 1,3-dicarbonyl compounds furnished